These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 17510644

  • 1. Stimulating the cell's appetite for itself.
    Simonsen A, Stenmark H.
    Nat Chem Biol; 2007 Jun; 3(6):304-6. PubMed ID: 17510644
    [No Abstract] [Full Text] [Related]

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V, Herrling P.
    Neurodegener Dis; 2007 Jun; 4(6):443-86. PubMed ID: 17934328
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO, Herrling P.
    Neurodegener Dis; 2005 Jun; 2(2):61-108. PubMed ID: 16909049
    [No Abstract] [Full Text] [Related]

  • 5. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B, Schellenberg GD.
    Int Rev Neurobiol; 2007 Jun; 77():219-46. PubMed ID: 17178476
    [No Abstract] [Full Text] [Related]

  • 6. Progesterone and progestins: neuroprotection and myelin repair.
    Schumacher M, Sitruk-Ware R, De Nicola AF.
    Curr Opin Pharmacol; 2008 Dec; 8(6):740-6. PubMed ID: 18929681
    [Abstract] [Full Text] [Related]

  • 7. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC, Drory VE.
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract] [Full Text] [Related]

  • 8. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.
    Exp Biol Med (Maywood); 2008 Nov; 233(11):vi. PubMed ID: 18957631
    [No Abstract] [Full Text] [Related]

  • 9. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R, Lestage P, Onteniente B, table ronde no 4 de Giens XXI (2005).
    Therapie; 2007 Nov; 62(6):463-72. PubMed ID: 18316011
    [No Abstract] [Full Text] [Related]

  • 10. Turning down, but not off.
    Lipton SA.
    Nature; 2004 Apr 01; 428(6982):473. PubMed ID: 15057811
    [No Abstract] [Full Text] [Related]

  • 11. Heteroarylnitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties.
    Porcal W, Hernández P, González M, Ferreira A, Olea-Azar C, Cerecetto H, Castro A.
    J Med Chem; 2008 Oct 09; 51(19):6150-9. PubMed ID: 18788732
    [Abstract] [Full Text] [Related]

  • 12. [Neurodegenerative diseases and tea].
    Barranco-Quintana JL, Allam MF, Del Castillo AS, Navajas RF.
    Rev Neurol; 2008 Oct 09; 44(6):381-2. PubMed ID: 17385176
    [No Abstract] [Full Text] [Related]

  • 13. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement.
    Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W.
    Neurobiol Dis; 2008 Oct 09; 32(1):16-25. PubMed ID: 18640276
    [Abstract] [Full Text] [Related]

  • 14. The role of autophagy in age-related neurodegeneration.
    McCray BA, Taylor JP.
    Neurosignals; 2008 Oct 09; 16(1):75-84. PubMed ID: 18097162
    [Abstract] [Full Text] [Related]

  • 15. Autophagy, lithium, and amyotrophic lateral sclerosis.
    Pasquali L, Longone P, Isidoro C, Ruggieri S, Paparelli A, Fornai F.
    Muscle Nerve; 2009 Aug 09; 40(2):173-94. PubMed ID: 19609902
    [Abstract] [Full Text] [Related]

  • 16. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO, Fischer F, Matthisson M, Herrling P.
    Neurodegener Dis; 2004 Aug 09; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract] [Full Text] [Related]

  • 17. New therapeutic strategies for treatment of neurodegenerative diseases.
    Kazantsev AG.
    Curr Pharm Des; 2009 Aug 09; 15(34):3917-8. PubMed ID: 20044916
    [No Abstract] [Full Text] [Related]

  • 18. Pathologically activated therapeutics for neuroprotection.
    Lipton SA.
    Nat Rev Neurosci; 2007 Oct 09; 8(10):803-8. PubMed ID: 17882256
    [Abstract] [Full Text] [Related]

  • 19. Dining in with BCL-2: new guests at the autophagy table.
    Germain M, Slack RS.
    Clin Sci (Lond); 2009 Oct 26; 118(3):173-81. PubMed ID: 19845510
    [Abstract] [Full Text] [Related]

  • 20. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, Jordán J.
    Rev Neurol; 2009 Oct 26; 47(1):31-8. PubMed ID: 18592478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.